Man Group plc Invests $1.51 Million in iRadimed Corporation $IRMD

Key Points

• Man Group plc purchased 15,847 iRadimed shares worth approximately $1.51 million during the second quarter, giving it a 0.12% stake. Institutional investors collectively own 92.34% of the company.
• Analyst sentiment remains positive but softened recently: Wall Street Zen and Weiss Ratings downgraded the stock to “Hold,” while the broader analyst consensus is still “Moderate Buy” with a $120 average price target.
• iRadimed beat quarterly estimates with $0.46 EPS and $20.47 million in revenue, and pays a quarterly dividend of $0.20, equivalent to an annualized $0.80 payout and a 0.9% yield.

Man Group plc purchased a new position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,847 shares of the medical equipment provider's stock, valued at approximately $1,514,000. Man Group plc owned about 0.12% of iRadimed at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. CWM LLC raised its holdings in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock valued at $64,000 after acquiring an additional 107 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 234 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in shares of iRadimed by 12.5% during the 1st quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider's stock worth $335,000 after purchasing an additional 387 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of iRadimed by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,782 shares of the medical equipment provider's stock valued at $466,000 after purchasing an additional 458 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen downgraded iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings cut iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $120.00.

iRadimed Price Performance

NASDAQ:IRMD opened at $86.17 on Thursday. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 48.14 and a beta of 0.89. The company's 50-day moving average is $92.56 and its two-hundred day moving average is $93.82. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The business had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities analysts anticipate that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were given a $0.20 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed's payout ratio is currently 44.69%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source